UNSPSC 51263002: Prazosin

This classification denotes an antihypertensive agent and alpha-adrenergic blocking agent with the molecular formula C19H21N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XM03YJ541D, chemically known as 4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazinyl 2-furyl ketone but generally known as prazosin, which bears US NIH Compound Identifier 4893. European Medicines Agency schedules Prazosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10011MIG.

UNSPSC 51263002 Prazosin is a Commodity code covering individual pharmaceutical products, but recent state and local procurement activity shows a marked mismatch between the code's nominal scope and what is actually being solicited. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through competitive bidding for community health initiatives, with quarterly deliveries to the Seminole County Community Health Building. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor intelligence on a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring how state agencies and self-insured health plans could contract directly with pharmaceutical manufacturers to improve prescription fulfillment efficiency. Neither solicitation targets prazosin specifically; both address broader pharmaceutical procurement mechanisms—one focused on emergency-response medications and drug deactivation systems, the other on systemic pharmacy benefit contracting models. The code shows little relevant recent activity aligned to its nominal product scope.

Activity is geographically dispersed across Florida and Texas, with issuing bodies spanning county health systems and state health and human services agencies. Seminole County's naloxone procurement required electronic bidding through the county e-Procurement Portal with a response deadline of July 26, 2023, and included requirements for E-Verify compliance, drug-free workplace certification, and workers' compensation insurance; the contract term was two years with a one-year renewal option. The Texas HHS RFI, closing April 3, 2026, functioned as a market-intelligence phase preceding formal procurement and did not identify budget ranges or set-aside designations. Neither opportunity is tagged to prazosin directly, indicating that the code assignment may reflect cataloging or classification inconsistency rather than active demand for this specific pharmaceutical product in state and local contracting.